Impel NeuroPharma is a privately-held, biotechnology company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel NeuroPharma is currently investigating INP104 (POD-DHE) for acute migraine headache, INP103 (POD-levodopa) for reversal of OFF episodes in Parkinson's disease and INP105 (POD-olanzapine) for acute agitation in schizophrenia and bipolar disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/06/18 | $67,500,000 | Series D |
5AM Ventures KKR  Norwest Venture Partners VenBio Vivo Capital | undisclosed |
